RxDoctor Payments Data

Caroline Taintor

Family · Union Beach, NJNPI 1144713546

Payments from drug & device makers

$4,424in general payments, 2019–2025

Across 177 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$901
  • Neurocrine Biosciences, Inc.$722
  • Johnson & Johnson$602
  • Otsuka America Pharmaceutical, Inc.$414
  • Teva Pharmaceuticals USA, Inc.$271
  • plus $450 from 6 others

What the payments were for

  • Food & beverage$4,34298%
  • Education$832%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,424 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$13,744
Medicare patients
16
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$113,676
AuvelityDextromethorphan Hbr/Bupropion11$11,191
Clozapine22$1,006
Lamotrigine34$854
Bupropion XlBupropion Hcl31$633
Duloxetine Hcl19$497
Famotidine13$457
Aripiprazole20$277
Fluoxetine Hcl16$230
Quetiapine Fumarate18$147
Sertraline Hcl28$124
Lithium Carbonate17$120
Escitalopram Oxalate37$106
Trazodone Hcl22$75
Gabapentin14$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$722$113,67613 claims
Axsome Therapeutics, Inc.Auvelity$116$11,19111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Union Beach

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →